Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sembiosys Genetics Inc. SBIYF

"SemBioSys Genetics Inc is engaged in developing high-value proteins and oils in plant seeds using its unique proprietary genetic expression and manufacturing technology platforms. The Company has operations in United States and Canada."


GREY:SBIYF - Post by User

Post by deelishuson Feb 08, 2012 7:37am
188 Views
Post# 19503599

5th Canada-China Business Forum and Signing Ceremo

5th Canada-China Business Forum and Signing Ceremo

SemBioSys and Tasly Pharmaceutical to participate in the 5th Canada-China Business Forum and Signing Ceremony

New Joint Venture Focused on Multi-Million Dollar Short-Term Revenue Opportunities

CALGARY, Feb. 8, 2012 /CNW/ - SemBioSys Genetics Inc. (TSX:SBS), today announced that it will be present at the 5th Canada-China Business Forum (CCBF) and Signing Ceremony on February 9, 2012, in Beijing, China. SemBioSys and its Chinese partner, Tasly Pharmaceutical Co., Ltd. are to sign supplementary documents necessary to establish the recently People's Republic of China approved Joint Venture.  The Joint Venture, based in Tianjin, China, called Tasly-SemBioSys Bio-Pharmaceutical Technology Co., Ltd., will commercialize near, medium, and long term healthy living, nutritional, and pharmaceutical products utilizing Tasly and SemBioSys' plant-based technology and expertise.

"The common values and scientific principles we share with Tasly Pharmaceutical and their approach to traditional Chinese medicine and biological drugs made our partnership a natural step in the progression of SemBioSys," said James Szarko, President and CEO of SemBioSys. "It is an honour to confirm our agreement at the Signing Ceremony and in the presence of Canada's own Prime Minister Harper."

<< Previous
Bullboard Posts
Next >>